TrialThe oncologist2022

A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.

Cecilia Monge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.